Press Releases AbbVie Inc.

Equities

ABBV

US00287Y1091

Pharmaceuticals

Market Closed - Nyse Other stock markets 21:00:03 08/05/2026 BST			5-day change	1st Jan Change
201.55 ^USD	-0.57%		-2.44%	-11.79%

05-05	AbbVie Inc. Presents New Long-Term Data For Skyrizi And Rinvoq In Inflammatory Bowel Diseases	CI
05-05	Daiwa Securities Adjusts AbbVie Price Target to $237 From $244, Maintains Outperform Rating	MT

Press Releases

05-06	AbbVie to Present at the Bank of America Securities Healthcare Conference	PR
05-05	AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®	PR
05-04	SKYRIZI® (risankizumab) Secures Listing on Ontario and Alberta Formularies in Ulcerative Colitis	AQ
04-30	AbbVie and adMare BioInnovations Announce RIME Therapeutics as AbbVie Biotech Innovators Award Recipient in Quebec	GL
04-30	Allergan Aesthetics Launches Philanthropic Effort in Recognition of Skin Cancer Awareness Month	PR
04-29	AbbVie : ABBV 1Q26 Press Release Final	PU
04-29	AbbVie: Q1 Earnings Snapshot	AQ
04-29	AbbVie Reports First-Quarter 2026 Financial Results	PR
04-28	AbbVie Submits Application to FDA for Upadacitinib (RINVOQ®) for Adults and Adolescents with Severe Alopecia Areata	PR
04-28	RINVOQ® (upadacitinib) Demonstrated Superiority Versus HUMIRA® (adalimumab) for Primary Endpoint in a Head-to-Head Study in Rheumatoid Arthritis Patients Who Have Failed First TNF inhibitor	AQ
04-27	AbbVie Submits Regulatory Application to FDA for SKYRIZI® (risankizumab-rzaa) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease	PR
04-24	AbbVie Provides Update on TrenibotulinumtoxinE Biologics License Application in the U.S.	AQ
04-23	AbbVie Provides Update on TrenibotulinumtoxinE (TrenibotE) Biologics License Application in the U.S.	PR
04-22	AbbVie Selects North Carolina for New $1.4 Billion Manufacturing Campus	PR
04-20	AbbVie and BioLabs Team Up to Support Life Sciences Innovation in Canada	AQ
04-14	Erin Lichy Gets Real About Her Natrelle® Breast Augmentation	PR
04-13	AbbVie Showcases Late-Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE) in Platinum-Sensitive Ovarian Cancer (PSOC) at SGO 2026	AQ
04-12	AbbVie Showcases Late‑Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE®) in Platinum‑Sensitive Ovarian Cancer (PSOC) at SGO 2026	PR
04-09	BOTOX(R) Cosmetic (onabotulinumtoxinA) Empowers Women Entrepreneurs Through 'The Confidence Collective' for Fourth Year	AQ
04-08	AbbVie : moves to close loopholes and strengthen accountability in 340B program	PU
04-08	BOTOX® Cosmetic (onabotulinumtoxinA) Empowers Women Entrepreneurs Through "The Confidence Collective" for Fourth Year	PR
04-08	AbbVie Defeats Genetic Privacy Class Action Because Request For Plaintiff's Family Medical History Was Not A "Condition Of Employment"	AQ
04-07	Allergan Aesthetics Third State-of-the-Art AMI Center Opens in Austin	PR
03-31	/C O R R E C T I O N -- AbbVie/	PR
03-31	AbbVie to Host First-Quarter 2026 Earnings Conference Call	PR